TABLE 3.

Performance of AST-GN69 and AST-NX06 cards compared to BMD for 26 A. baumannii isolates

Antimicrobiala	BPb	No. of isolatesc				Performance (no. [%])d
		Total	R	I	S	EA	CA	VMEs	MEs	mEs
SAM	V2/C	26	7	6	13	26 (100)	18 (69.2)	0 (0)	0 (0)	8 (30.7)
TZP	V2/C	26	13	2	11	26 (100)	23 (88.5)	0 (0)	0 (0)	3 (11.5)
Cefepime	V2/C	26	10	4	12	26 (100)	21 (80.8)	0 (0)	0 (0)	5 (19.2)
Cefotaxime	V2/C	26	14	8	6	26 (100)	23 (88.5)	0 (0)	0 (0)	3 (11.5)
Ceftazidime	V2/C	26	13	1	12	25 (96.2)	24 (85.7)	0 (0)	0 (0)	4 (15.4)
Ceftriaxone	V2/C	26	13	7	6	25 (96.2)	20 (76.9)	0 (0)	0 (0)	6 (23.1)
Doripenem	V2	26	13	0	13	26 (100)	26 (100)	0 (0)	0 (0)	0 (0)
	CLSI	26	14	0	12	26 (100)	25 (96.2)	0 (0)	0 (0)	1 (3.8)
Imipenem	V2	26	10	0	16	26 (100)	26 (100)	0 (0)	0 (0)	0 (0)
	CLSI	26	10	1	15	26 (100)	26 (100)	0 (0)	0 (0)	0 (0)
Meropenem	V2	26	10	1	15	26 (100)	26 (100)	0 (0)	0 (0)	0 (0)
	CLSI	26	11	1	14	26 (100)	25 (96.2)	0 (0)	0 (0)	1 (3.8)
Gentamicin	V2/C	26	11	0	15	26 (100)	26 (100)	0 (0)	0 (0)	0 (0)
Tobramycin	V2/C	26	10	0	16	25 (96.2)	23 (88.5)	1 (10.0)	0 (0)	2 (7.7)
Ciprofloxacin	V2/C	26	14	0	12	26 (100)	26 (100)	0 (0)	0 (0)	0 (0)
Levofloxacin	V2/C	26	14	0	12	26 (100)	26 (100)	0 (0)	0 (0)	0 (0)
SXT	V2/C	26	13	0	13	26 (100)	26 (100)	0 (0)	0 (0)	0 (0)

^aSAM, ampicillin-sulbactam; TZP, piperacillin-tazobactam; SXT, trimethoprim-sulfamethoxazole.

^bBP, breakpoint used to interpret MIC results; V2/C, Vitek 2 and CLSI M100S 26th edition breakpoints are the same; V2, Vitek 2 reported breakpoints; CLSI, M100S 26th edition breakpoints.

^cR, resistant; I, intermediate; S, susceptible.

^dEA, essential agreement (MIC ±1 doubling dilution); CA, categorical agreement; VMEs, very major errors; MEs, major errors; mEs, minor errors.